Search Result

Results for "

ALK Receptors Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Anaplastic lymphoma kinase (ALK) (4) AMPK (2) Apoptosis (1) Autophagy (2) IGF-1R (1) Insulin Receptor (1) Organoid (9) TGF-beta/Smad (1) TGF-β Receptor (29) Trk Receptor (1)
By Research Areas:	Cancer (32) Endocrinology (1) Inflammation/Immunology (3) Metabolic Disease (1)

Inhibitors & Agonists

Screening Libraries

Targets Recommended: Anaplastic lymphoma kinase (ALK)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13521

SB-505124 15+ Cited Publications	TGF-β Receptor	Cancer
SB-505124 is a selective inhibitor of TGF-β Receptor type I receptors (ALK4, *ALK5, ALK7), with IC₅₀s of 129 nM and 47 nM for ALK4, ALK5, respectively, but it does not inhibit* ALK1, 2, 3, or 6.

HY-13521A

SB-505124 hydrochloride 15+ Cited Publications	TGF-β Receptor	Cancer
SB-505124 hydrochloride is a selective inhibitor of TGF-β Receptor type I receptor (ALK4, *ALK5, ALK7), with IC₅₀s of 129 nM and 47 nM for ALK4, ALK5, respectively, but it does not inhibit* ALK1, 2, 3, or 6.

HY-10432

A 83-01 35+ Cited Publications	Organoid TGF-β Receptor	Cancer
A 83-01 is a potent inhibitor of TGF-β type I receptor ALK5 kinase, type I nodal receptor *ALK4* and type I nodal receptor *ALK7, with IC₅₀s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4* and *ALK7*, respectively .

HY-151272

ALK5-IN-26	Others	Cancer
ALK5-IN-26 (EX-22) is an *ALK* (Activin receptor-like kinase) inhibitor. ALK5-IN-26 inhibits ALK5 with an IC₅₀ value ≤10 nM. ALK5-IN-26 can be used for the research of cancer .

HY-151277

ALK5-IN-29	Anaplastic lymphoma kinase (ALK)	Cancer
ALK5-IN-29 is an selective activin receptor-like kinase (ALK) inhibitor. ALK5-IN-29 can inhibit the activity of ALK5 with an IC₅₀ value of ≤10 nM. ALK5-IN-29 also has inhibitory of tumor growth and can be used for the research of proliferative diseases, such as cancer .

HY-151289

ALK5-IN-34	TGF-β Receptor TGF-beta/Smad	Cancer
ALK5-IN-34 is an selective orally active activin receptor-like kinase (ALK) inhibitor. ALK5-IN-34 can inhibit the activity of ALK5-IN-34 with an IC₅₀ value of ≤10 nM. ALK5-IN-34 also has inhibitory of tumor growth and can be used for the research of proliferative diseases, such as cancer .

HY-10432A

A 83-01 sodium 35+ Cited Publications	Organoid TGF-β Receptor	Cancer
A 83-01 sodium is a potent inhibitor of *TGF-β type I receptor* ALK5 kinase, ALK4 and ALK7, with IC₅₀s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7**, respectively .

HY-12071A

LDN193189 Tetrahydrochloride 45+ Cited Publications DM-3189 Tetrahydrochloride	Organoid TGF-β Receptor	Cancer
LDN193189 Tetrahydrochloride is a selective BMP type I receptor inhibitor, which efficiently inhibits *ALK2* and *ALK3* (IC₅₀=5 nM and 30 nM, respectively), with weaker effects on ALK4, ALK5 and ALK7 (IC₅₀≥500 nM) .

HY-112815

ALK2-IN-2 1 Publications Verification	TGF-β Receptor	Cancer
ALK2-IN-2 is a potent and selective inhibitor of activin receptor-like kinase 2 (ALK2) with an IC₅₀ of 9 nM, and over 700-fold selectivity against ALK3 .

HY-151233

ALK5-IN-10	TGF-β Receptor	Cancer
ALK5-IN-10 (Compound 5d) is a TGF-β type I receptor kinase *ALK5* inhibitor, with IC₅₀s of 0.007 and 1.98 μM for ALK5 and p38α, respectively. ALK5-IN-10 can be used for the research of cancer .

HY-117887

Fidrisertib BLU-782; IPN-60130; ALK2-IN-1	TGF-β Receptor	Cancer
ALK2-IN-1 is a activin receptor-like kinase-2 (ALK2) inhibitor extracted from patent WO2017181117A1, Compound 876, has an IC₅₀ of <10 nM .

HY-12278

K02288 2 Publications Verification	TGF-β Receptor	Others
K02288 is a potent bone morphogenetic protein (BMP) type I receptor inhibitor with IC₅₀s of 1.8, 1.1, 6.4 nM for ALK1, ALK2 and ALK6, respectively. K02288 shows slightly weaker inhibition against ALK3 and ALK6 with IC₅₀s of of 5-34 nM.

HY-13418

Dorsomorphin dihydrochloride Maximum Cited Publications 453 Publications Verification Compound C dihydrochloride; BML-275 dihydrochloride	Organoid AMPK TGF-β Receptor Autophagy	Cancer
Dorsomorphin (Compound C) dihydrochloride is a potent, selective and ATP-competitive AMPK inhibitor, with a K_i of 109 nM. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptors *ALK2, ALK3, and ALK6*. Dorsomorphin dihydrochloride can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599).

HY-19928

Vactosertib 3 Publications Verification EW-7197; TEW-7197	TGF-β Receptor	Cancer
Vactosertib (EW-7197) is a potent, orally active and ATP-competitive activin receptor-like kinase 5 (ALK5) inhibitor with an IC₅₀ of 12.9 nM. Vactosertib also inhibits ALK2 and ALK4 (IC₅₀ of 17.3 nM) at nanomolar concentrations. Vactosertib has potently antimetastatic activity and anticancer effect .

HY-19928A

Vactosertib Hydrochloride 3 Publications Verification EW-7197 Hydrochloride; TEW-7197 Hydrochloride	TGF-β Receptor	Cancer
Vactosertib Hydrochloride (EW-7197 Hydrochloride) is a potent, orally active and ATP-competitive activin receptor-like kinase 5 (ALK5) inhibitor with an IC₅₀ of 12.9 nM. Vactosertib Hydrochloride also inhibits ALK2 and ALK4 (IC₅₀ of 17.3 nM) at nanomolar concentrations. Vactosertib Hydrochloride has potently antimetastatic activity and anticancer effect .

HY-13418A

Dorsomorphin Maximum Cited Publications 453 Publications Verification Compound C; BML-275	Organoid AMPK TGF-β Receptor Autophagy	Cancer
Dorsomorphin (Compound C) is a selective and ATP-competitive AMPK inhibitor (K_i=109 nM in the absence of AMP). Dorsomorphin (BML-275) selectively inhibits BMP type I receptors *ALK2, ALK3, and ALK6. Dorsomorphin can reverse autophagy* activation and anti-inflammatory effect of Urolithin A (HY-100599) .

HY-10326

GW788388 10+ Cited Publications	TGF-β Receptor	Cancer
GW788388 is a potent and selective inhibitor of *ALK5* with IC₅₀ of 18 nM, and also inhibits TGF-β type II receptor and activin type II receptor activities, without inhibiting BMP type II receptor.

HY-142949

ALK5-IN-7	TGF-β Receptor	Inflammation/Immunology Cancer
ALK5-IN-7 is a potent inhibitor of *ALK5. Transforming growth factor beta (TGF-β) is a multifunctional cytokine that is involved in regulating cell proliferation, differentiation and apoptosis through complex receptor* signaling pathways on the cell surface in an autocrine, paracrine and endocrine manner. ALK5-IN-7 has the potential for the research of TGF-β-related diseases and conditions, including but not limited to tumors, fibrotic diseases, inflammatory diseases, autoimmune diseases, etc (extracted from patent WO2021129621A1, compound 4) .

HY-142950

ALK5-IN-6	TGF-β Receptor	Inflammation/Immunology Cancer
ALK5-IN-6 is a potent inhibitor of *ALK5. Transforming growth factor beta (TGF-β) is a multifunctional cytokine that is involved in regulating cell proliferation, differentiation and apoptosis through complex receptor* signaling pathways on the cell surface in an autocrine, paracrine and endocrine manner. ALK5-IN-6 has the potential for the research of TGF-β-related diseases and conditions, including but not limited to tumors, fibrotic diseases, inflammatory diseases, autoimmune diseases, etc (extracted from patent WO2021129621A1, compound 1) .

HY-12071

LDN193189 45+ Cited Publications DM-3189	Organoid TGF-β Receptor	Cancer
LDN193189 is a potent selective *BMP type I receptor* (BMP I)** inhibitor. LDN-193189 efficiently inhibits transcriptional activity of the BMP type I receptors *ALK2* and *ALK3* with IC₅₀ values of 5 nM and 30 nM, respectively. LDN-193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva .

HY-12043

SB 525334

5+ Cited Publications

TGF-β Receptor Cancer

SB 525334 is a potent and selective transforming growth factor β1 receptor (ALK5) inhibitor with an IC₅₀ of 14.3 nM.

SB 525334 5+ Cited Publications	TGF-β Receptor	Cancer
SB 525334 is a potent and selective transforming growth factor β1 receptor *(ALK5)* inhibitor with an IC₅₀ of 14.3 nM.

HY-152845

Ficonalkib	Anaplastic lymphoma kinase (ALK)	Cancer
Ficonalkib is a potent inhibitor of Anaplastic lymphoma kinase (ALK), the tyrosine kinase receptor. Ficonalkib, can be used as an antineoplastic agent .

HY-18758

IN-1130 1 Publications Verification
IN-1130 is a highly selective transforming growth factor-β type I receptor kinase (ALK5) inhibitor with an IC₅₀ of 5.3 nM for ALK5-mediated Smad3 phosphorylation. IN-1130 inhibits ALK5 phosphorylation of casein (IC₅₀=36 nM) and p38α mitogen-activated protein kinase (IC₅₀=4.3 μM). IN-1130 suppresses renal fibrosis in obstructive nephropathy and blocks breast cancer lung metastasis .

HY-12071B

LDN-193189 dihydrochloride 45+ Cited Publications DM-3189 dihydrochloride	TGF-β Receptor Organoid	Cancer
LDN-193189 (dihydrochloride) is a potent selective *BMP type I receptor* (BMP I)** inhibitor. LDN-193189 efficiently inhibits transcriptional activity of the BMP type I receptors *ALK2* and *ALK3* with IC₅₀ values of 5 nM and 30 nM, respectively. LDN-193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva .

HY-13783

BIBF0775

TGF-β Receptor Cancer

BIBF0775 is a potent and selective transforming growth factor β (TGFβ) type I receptor (Alk5) inhibitor with an IC₅₀ of 34 nM.

BIBF0775	TGF-β Receptor	Cancer
BIBF0775 is a potent and selective transforming growth factor β (TGFβ) type I receptor (Alk5) inhibitor with an IC₅₀ of 34 nM.

HY-10431

SB-431542 160+ Cited Publications	Organoid TGF-β Receptor Apoptosis	Cancer
SB-431542 is a *TGF-β receptor* kinase inhibitor (TRKI)*. SB-431542 has inhibitory activity for ALK4, ALK5 and ALK7 with IC₅₀* values of 1 μM, 0.75 μM and 2 μM, respectively. SB-431542 also inhibits TGF-β-induced transcription, gene expression, apoptosis, and growth suppression. SB-431542 can be used for the research of cancer and signal transduction pathways .

HY-13020

GSK1838705A 5+ Cited Publications	Anaplastic lymphoma kinase (ALK) IGF-1R Insulin Receptor	Endocrinology Cancer
GSK1838705A is a potent and reversible IGF-IR and the insulin receptor inhibitor with IC₅₀s of 2.0 and 1.6 nM, respectively. It also inhibits *ALK* with an IC₅₀ of 0.5 nM.

HY-78349

A 77-01 1 Publications Verification	TGF-β Receptor	Cancer
A 77-01 is a potent inhibitor of transforming growth factor (TGF)-β type I receptor superfamily activin-like kinase ALK5 with an IC₅₀ of 25 nM .

HY-13012

RepSox 15+ Cited Publications E-616452; SJN 2511	Organoid TGF-β Receptor	Metabolic Disease
RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC₅₀ value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes .

HY-149403

J-1048	Anaplastic lymphoma kinase (ALK)	Others
J-1048 is an activin receptor-like kinase 5 *(ALK5)* inhibitor. J-1048 can inhibit TAA-induced liver fibrosis in mice by explicitly blocking the TGF-β/Smad signaling pathway .

HY-161377

M4K2306	TGF-β Receptor	Cancer
M4K2306 is a selective inhibitor for activin receptor-like kinase-2 (ALK2) with an IC₅₀ of 7 nM. M4K2306 is blood brain permeable with a brain to plasma ratio of 75.6 .

HY-103021

LY3200882 5+ Cited Publications	TGF-β Receptor	Inflammation/Immunology Cancer
LY3200882 is a potent, highly selective, ATP-competitive and orally active TGF-β receptor type 1 (ALK5) inhibitor with an IC₅₀ of 38.2 nM. LY3200882 inhibits various pro-tumorigenic activities and is also used as an immune modulatory agent .

HY-161376

M4K2281	TGF-β Receptor	Cancer
M4K2281 is a selecitve inhibitor for activin receptor-like kinase-2 (ALK2) with an IC₅₀ of 2 nM. M4K2281 exhibits a moderate blood brain permeability with a brain to plasma ratio of 3.7 at 4h .

HY-155939

M4K2163 dihydrochloride	TGF-β Receptor	Cancer
M4K2163 dihydrochloride is a potent, selective, blood-brain barrier (BBB) permeable activin receptor-like kinase-2 (ALK2) inhibitor, with an IC₅₀ of 19 nM. M4K2163 dihydrochloride can be used in the research of diffuse intrinsic pontine glioma (DIPG) .

HY-144423

Trk-IN-10	Trk Receptor	Cancer
Trk-IN-10 (Compound 14j) is a potent inhibitor of TRK (IC₅₀ = 0.86, 6.92 nM, against TrkA, TrkA ^G595R, respectively). As a receptor tyrosine kinase (RTK), tropomyosin receptor kinase (Trk) is a key agent target in solid tumors. Trk-IN-10 (IC₅₀ = 350 nM against ALK) has a higher selectivity of Trk inhibition, which may be of great significance for reducing toxicity .

HY-146780

TGFβRI-IN-4	TGF-β Receptor	Cancer
TGFβRI-IN-4 is a highly potent and orally active *TGFβ receptor* type I (TGFβRI)** inhibitor, with IC₅₀s of 44 nM and 42.5 nM for ALK5 and NIH3T3. TGFβRI-IN-4 can suppress tumor growth and tumor weight in tumor xenograft model .

Protein Tyrosine Kinase Compound Library	1064 compounds
Protein tyrosine kinases (PTKs) are key signaling molecules and important drug targets. Two classes of PTKs are present in cells: the transmembrane receptor PTKs (RTKs) and the nonreceptor PTKs. The RTK family includes the receptors for insulin and for many growth factors, such as EGFR, FGFR, PDGFR, VEGFR, and NGFR. RTKs are transmembrane glycoproteins that are activated by the binding of their ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. Their principal functions of PTKs involve the regulation of multicellular aspects of the organism. Cell to cell signals concerning growth, differentiation, adhesion, motility, and death are frequently transmitted through tyrosine kinases. In humans, tyrosine kinases have been demonstrated to play significant roles in the development of many disease states, including diabetes and cancers. MCE designs a unique collection of 1064 compounds that act as a useful tool for PTKs-related drug screening and disease research.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: